Skip to main content

Table 3 The treatment-related any-grade adverse events and grade 3/4 adverse events

From: Phase II study of sequential S-1 and cyclophosphamide therapy in patients with metastatic breast cancer

Adverse Events, (n) All Grade Grade 3/4
Leukopenia 7 (19.4%) 5 (13.9%)
Anemia 1 (2.8%) 1 (2.8%)
Thrombocytopenia 3 (8.3%) 1 (2.8%)
Fatigue 3 (8.3%) 0
Nasolacrimal duct obstruction 1 (2.8%) 0
Sepsis 1 (2.8%) 1 (2.8%)
\